Advance your diagnosis with Multiplex PCR Assays
GeneMatrix is undergoing a transformation for diagnostic innovation with the slogan "Advance your diagnosis,"
striving to be a company that contributes to people's healthy lives through molecular diagnostics.
History
2022
Launched NeoPlex™ HPV and NeoPlex™ TB/NTM products.
Genematrix has strengthened its product lineup across various panels to respond to global trends in infectious diseases.
Genematrix has strengthened its product lineup across various panels to respond to global trends in infectious diseases.
2022
Completed pre-clinical trials for Hepatitis A vaccine.
Research for vaccine development is undergoing.
Research for vaccine development is undergoing.
2020
Released NeoPlex™ COVID-19 and received emergency use authorization from the U.S. FDA. Contributed to overcoming the pandemic by participating as a supplier for UNICEF diagnostic kits.
2019
Obtained a U.S. patent for the proprietary multiplex diagnostic technology C-Tag™. This core technology has been utilized in the development of NeoPlex™ products.
2018
Expanded CE certification for the NeoPlex™ product line.
Market competitiveness is strengthened by responding to In Vitro Diagnostic Regulation(IVDR) and expanding exports.
Market competitiveness is strengthened by responding to In Vitro Diagnostic Regulation(IVDR) and expanding exports.
2017
Launched NeoPlex™, a multiplex real-time PCR test.
The product line will be further developed over the next few years.
The product line will be further developed over the next few years.
2013
Released diagnostic products based on RFMP technology for diseases such as Hepatitis B, Hepatitis C, cervical cancer, and liver cancer.
2011
Acquired HBI, a specialized company in the field of biochemical diagnostics. Started the development and sale of general and special biochemical diagnostic reagents.
2009
Listed on the KOSDAQ stock market with technical exemptions.
2003
Licensed out RFMP technology for DNA mutation analysis.
2000
GeneMatrix Inc was established for the purpose of developing diagnostic products and new therapeutics through genetic mutation research.
